# GENELUX Corp: overview

GNLX · Nasdaq · CIK 1231457 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gnlx.md) · [Financials](/companies/gnlx/financials.md) · [Filings](/companies/gnlx/filings.md) · [Insiders](/companies/gnlx/insiders.md)

Latest reported revenue: [$0](/filings/0001493152-26-011616.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 19, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-011616).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0 d](/filings/0001493152-25-020874.md) | [0.0 d](/filings/0001493152-26-011616.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.19)](/filings/0001493152-25-020874.md) | not reported | [(0.21)](/filings/0001493152-26-021710.md) | [(0.20)](/filings/0001493152-26-037667.md) | [(0.21)](/filings/0001493152-25-020874.md) | not reported | [(0.20)](/filings/0001493152-26-021710.md) | [(0.21)](/filings/0001493152-26-037667.md) |
| Free cash flow | $k | [(5,775) d](/filings/0001493152-25-020874.md) | [(4,398) d](/filings/0001493152-26-011616.md) | [(5,465)](/filings/0001493152-26-021710.md) | [(7,174) d](/filings/0001493152-26-037667.md) | [(7,092) d](/filings/0001493152-25-020874.md) | [(6,635) d](/filings/0001493152-26-011616.md) | [(6,980)](/filings/0001493152-26-021710.md) | [(7,976) d](/filings/0001493152-26-037667.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.1](/filings/0001493152-24-011946.md) | [0.2](/filings/0001641172-25-001184.md) | [0.0](/filings/0001493152-26-011616.md) | [0.0](/filings/0001493152-26-011616.md) |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | [(27.2%)](/filings/0001493152-24-011946.md) | [(14214.7%)](/filings/0001641172-25-001184.md) | [(396200.0%)](/filings/0001493152-26-011616.md) | [(415175.0%)](/filings/0001493152-26-011616.md) |
| Net margin | % | [(47.0%)](/filings/0001493152-24-011946.md) | [(16645.3%)](/filings/0001641172-25-001184.md) | [(373362.5%)](/filings/0001493152-26-011616.md) | [(401812.5%)](/filings/0001493152-26-011616.md) |
| Diluted EPS | $ per share | [(0.57)](/filings/0001493152-24-011946.md) | [(1.16)](/filings/0001641172-25-001184.md) | [(0.95)](/filings/0001493152-26-011616.md) | [(0.86)](/filings/0001493152-26-011616.md) |
| Free cash flow | $m | [(3.6)](/filings/0001493152-24-011946.md) | [(21.3)](/filings/0001641172-25-001184.md) | [(21.6)](/filings/0001493152-26-011616.md) | [(26.4)](/filings/0001493152-26-011616.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gnlx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [WOODWARD DIVERSIFIED CAPITAL, LLC](/funds/1846177.md) | 2026-06-30 | $6.8m | 2,262,108 |  | Added +144,925 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.0m | 1,677,724 |  | Reduced −17,756 |
| [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $4.2m | 1,380,666 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.3m | 439,602 |  | Added +33,730 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.3m | 439,213 |  | Reduced −14,548 |
| [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $1.2m | 400,000 |  | Added +150,000 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $989.7k | 328,803 |  | Added +4,938 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $711.4k | 236,344 |  | Reduced −15,266 |
| [FLPUTNAM INVESTMENT MANAGEMENT CO](/funds/1140334.md) | 2026-06-30 | $696.5k | 231,405 |  | Reduced −49,499 |
| [Global Retirement Partners, LLC](/funds/1749744.md) | 2026-06-30 | $685.8k | 227,854 |  | Not compared |

## Recent filings

[All 351 filings](/companies/gnlx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 13:05 ET | [10-Q](/filings/0001493152-26-037667.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037667 |
| 2026-06-22 | 16:45 ET | [8-K](/filings/0001493152-26-029607.md) | 5.07 Shareholder vote results | 0001493152-26-029607 |
| 2026-05-07 | 16:07 ET | [10-Q](/filings/0001493152-26-021710.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021710 |
| 2026-04-29 | 08:00 ET | [DEF 14A](/filings/0001493152-26-019473.md) | Proxy statement, period 2026-04-29 | 0001493152-26-019473 |
| 2026-03-19 | 16:52 ET | [8-K](/filings/0001493152-26-011649.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-011649 |
| 2026-03-19 | 16:05 ET | [10-K](/filings/0001493152-26-011616.md) | Annual report, period 2025-12-31 | 0001493152-26-011616 |
| 2026-02-02 | 16:16 ET | [8-K](/filings/0001493152-26-004755.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-004755 |
| 2026-01-08 | 17:09 ET | [8-K](/filings/0001493152-26-000989.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-000989 |
| 2026-01-05 | 08:15 ET | [8-K](/filings/0001493152-26-000270.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-000270 |
| 2026-01-02 | 16:10 ET | [8-K](/filings/0001493152-26-000115.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-000115 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-011616.md), filed Mar 19, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1231457
- Tickers: GNLX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.